Atherothrombosis: Plaque instability and thrombogenesis

Progress in Cardiovascular Diseases

Volumn 44, Issue 5, 2002, Pages 381-394

  Ruberg, Frederick L ^a   Leopold, Jane A ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACOVA; ALTEPLASE; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ATORVASTATIN; CELL ADHESION MOLECULE; CLOPIDOGREL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE PROTEIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HEMOSTASIS; HUMAN; MACROPHAGE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; THROMBOGENESIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0036098224     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.123469     Document Type: Article

References (110)

1. Cellular adhesion molecules and atherogenesis
2. The combined role of P- and E- selectins in atherosclerosis
3. The transcription factor NF-kappa B and the regulation of vascular cell function
4. Engagement of human PECAM-1 (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release
5. Cell adhesion in vascular biology. New insights into integrin-ligand interaction
6. Platelet membranes and receptors
7. Mechanisms of platelet activation
8. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets
9. Nitric oxide insufficiency, platelet activation, and Arterial thrombosis
10. Endothelial injury, vasoconstriction, and its prevention
11. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39
12. Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: Requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment
13. Vascular-bed-specific hemostasis and hypercoagulable states
14. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
15. Atherosclerosis
16. Oxidative stress as a regulator of gene expression in the vasculature
17. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress
18. Diabetes, oxidative stress, and platelet activation
19. Atherosclerosis: From lesion formation to plaque activation and endothelial dysfunction
20. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E- selectin in human atherosclerosis
21. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse
22. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection
23. CD 36 in atherosclerosis. The role of a class B macrophage scavenger receptor
24. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
25. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA 1 pathway
26. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
27. Cytokines and growth factors in atherogenesis
28. Oxidant stress-induced transendothelial migration of monocytes is linked to phosphorylation of PECAM-1
29. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells
30. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells
31. Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro
32. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: Induction by transforming growth factor-beta, lipo-polysaccharide, and tumor necrosis factor-alpha
33. Transforming growth factor beta 1 and beta 2 induce down-modulation of thrombomodulin in human umbilical vein endothelial cells
34. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives
35. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
36. Nitric oxide and atherosclerosis
37. Workshop: Hypertension and cardiovascular risk factors: Role of the angiotensin II-nitric oxide interaction
38. Angiotensin II and atherosclerosis
39. The extracellular matrix dynamically regulates smooth muscle cell responsiveness to PDGF
40. Relation between endothelial dys-function and the acute coronary syndrome: Implications for therapy
41. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells
42. Changing concepts of atherogenesis
43. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atheroselerotic plaques
44. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
45. Tissue inhibitors of metalloproteinases: Evolution, structure and function
46. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
47. The CD40/CD154 receptor/ligand dyad
48. Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease
49. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study
50. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study
51. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial
52. Aspirin, heparin, or both to treat acute unstable angina
53. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myo-cardial infarction
54. The basic pharmacology of ticlopidine and clopidogrel
55. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAP-RIE)
56. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial
57. Results of CURE trial for acute coronary syndrome
58. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and av/β 3 integrins
59. Platelet GPIIb-IIIa blockers
60. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists
61. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
62. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndormes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
63. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
64. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation
65. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary re-vascularization
66. Randomised placebo-controlled and balloon-angio-plasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting
67. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
68. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
69. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes
70. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
71. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events
72. Redefining medical treatment in the management of unstable angina
73. Clinical uses of low-molecular-weight heparins
74. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin in unstable coronary artery disease study (FRIC)
75. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
76. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-Wave myocardial infarction results of the thrombolysis in myocardial infarction (TIMI) 11B trial
77. The mechanism of action of thrombin inhibitors
78. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevationa randomised trial
79. Recombinant hirudin in clinical practice: Focus on lepirudin
80. The role of bivalirudin in percutaneous coronary intervention
81. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin usersprimary end points analysis from the ATACS trial
82. Oral anticoagulant therapy in patients with coronary artery diseasea meta-analysis
83. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
84. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke treatment with ancrod trial
85. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
86. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
87. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 trial
88. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial
89. 10 Year survival among patients with suspected acute myo-cardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither
90. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction, results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study
91. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
92. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
93. Effects of HMG-CoA reductase inhibitor on hemostasis
94. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs
95. Coronary artery injury and the biology of atherosclerosis: Inflammation, thrombosis, and stabilization
96. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
97. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
98. Angiotensin, fibrinolysis, and vascular homeostasis
99. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
100. Risk stratification in unstable angina and non-Q wave myo-cardial infarction using soluble cell adhesion molecules
101. Soluble adhesion molecules and unstable coronary artery disease
102. Both early and delayed anti-CD 40L antibody treatment induces a stable plaque phenotype
103. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
104. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
105. Nonhypoglycemic effects of thiazolidinediones
106. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model
107. Thrombo-modulin overexpression to limit neointima formation
108. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor
109. Therapeutic potential of nitric oxide synthase gene manipulation